Plasma Oxalate in Patient With Short Bowel

Hyperoxaluria due to fat malabsorption is seen in patients suffering from short bowel and can lead to stones and nephrocalcinosis. Not all patients are prone to these renal complications. only urinary oxaluria is measured in practice. Plasma oxalate shouldn't increase theoretically in these patients. However recent report showed an increase of plasma oxalate in patient with enteric hyperoxaluria. The aim of this study is to assess the plasma oxalate distribution in this specific population to have a new tool to predict renal complication of these patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Short Bowel Syndrome Digestive System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Hyperoxalemia Hyperoxaluria Intestinal Diseases Kidney Diseases Malabsorption Syndromes Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nephrology Department, Edouard Herriot Hospital

Lyon, 69003, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Type II short bowel for more than 6 months
Affiliated to a social health care

Exclusion criteria

Primary hyperoxaluria
Other type of short bowel than type II
Minor patient or major patient protected by the law

Treatment and study plan

Blood sampling

Biological

blood sampling will be used to perform oxalemia and FGF23 quantitative analysis

Urine sampling

Biological

urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis

Pulse Wave Velocity (PWV) measurement

Procedure

PWV will be measured thank to the Complior® device

central pressure measurement

Procedure

central pressure will be measured thank to the Complior® device

Primary outcomes

Plasma oxalate rate (oxalemia)

Time frame: at inclusion

this sample measures the plasma oxalate rate

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: OXAGO

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Oct 8, 2019
Registry last updated: Jul 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed